Ignite Creation Date:
2025-12-25 @ 2:03 AM
Ignite Modification Date:
2026-03-13 @ 8:40 AM
Study NCT ID:
NCT03731260
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-23
First Post:
2018-10-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
Sponsor:
Blueprint Medicines Corporation
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-04-16
Start Date Type:
ACTUAL
Primary Completion Date:
2027-06-23
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06-23
Completion Date Type:
ESTIMATED
First Submit Date:
2018-10-30
First Submit QC Date:
None
Study First Post Date:
2018-11-06
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-22
Last Update Post Date:
2025-09-23
Last Update Post Date Type:
ESTIMATED